Statin myotoxicity: A review of genetic susceptibility factors

Neuromuscular Disorders

Volumn 24, Issue 1, 2014, Pages 4-15

  Needham, M ^a   Mastaglia, F L ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A (HMGCoA) reductase inhibitors; Genetics; Muscle; Myalgia; Myopathy; Pharmacogenomics; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CETP GENE; COQ2 GENE; CREATININE BLOOD LEVEL; CYP3A5 GENE; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TRANSPORT; DRUG UPTAKE; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HMGCR GENE; HOMOZYGOSITY; HUMAN; MYALGIA; MYOPATHY; PATHOGENESIS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B1 GENE; UNSPECIFIED SIDE EFFECT;

3-HYDROXY-3-METHYLGLUTARYL COENZYME A (HMGCOA) REDUCTASE INHIBITORS; GENETICS; MUSCLE; MYALGIA; MYOPATHY; PHARMACOGENOMICS; STATINS;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; PHARMACOGENETICS; RISK FACTORS;

EID: 84891944468     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2013.09.011     Document Type: Review

References (147)

1. Ruano G., Windemuth A., Wu A.H., et al. Mechanisms of statin-induced myalgia assessed by physiogenomic associations. Atherosclerosis 2011, 218:451-456.
2. Vladutiu G.D. Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008, 20:648-655.
3. Sung J.C., Nichol M.B., Venturini F., Bailey K.L., McCombs J.S., Cody M. Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care 1998, 4:1421-1430.
4. Andrade S.E., Walker A.M., Gottlieb L.K., et al. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings?. N Engl J Med 1995, 332:1125-1131.
5. Cham S., Evans M.A., Denenberg J.O., Golomb B.A. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy 2010, 30:541-553.
6. Draeger A., Monastyrskaya K., Mohaupt M., et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006, 210:94-102.
7. Armitage J. The safety of statins in clinical practice. Lancet 2007, 370:1781-1790.
8. Meador B.M., Huey K.A. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve 2010, 42:469-479.
9. Newman C.B., Palmer G., Silbershatz H., Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9416 patients. Am J Cardiol 2003, 92:670-676.
10. Newman C., Tsai J., Szarek M., Luo D., Gibson E. Comparative safety of atorvastatin 80mg versus 10mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006, 97:61-67.
11. Ridker P.M., Danielson E., Fonseca F.A.H., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
12. Nichols G.A., Koro C.E. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther 2007, 29:1761-1770.
13. Bruckert E., Hayem G., Dejager S., Yau C., Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005, 19:403-414.
14. Cohen J.D., Brinton E.A., Ito M.K., Jacobson T.A. Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 2012, 6:208-215.
15. Abd T.T., Jacobson T.A. Statin-induced myopathy: a review and update. Expert Opin Drug Saf 2011, 10:373-387.
16. Law M., Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol 2006, 97:52C-60C.
17. Graham D.J., Staffa J.A., Shatin D., et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004, 292:2585-2590.
18. Chan J., Hui R.L., Levin E. Differential association between statin exposure and elevated levels of creatine kinase. Ann Pharmacother 2005, 39:1611-1616.
19. Thompson P.D., Clarkson P.M., Rosenson R.S. An assessment of statin safety by muscle experts. Am J Cardiol 2006, 97:69C-76C.
20. Jacobson T.A. Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008, 83:687-700.
21. Pasternak R.C., Smith S.C., Bairey-Merz C.N., Grundy S.M., Cleeman J.I., Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 2002, 33:2337-2341.
22. Feng Q., Wilke R.A., Baye T.M. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics 2012, 13:579-594.
23. Flint O.P., Masters B.A., Gregg R.E., Durham S.K. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 1997, 145:91-98.
24. Tiwari A., Bansal V., Chugh A., Mookhtiar K. Statins and myotoxicity: a therapeutic limitation. Expert Opin Drug Saf 2006, 5:651-666.
25. Zhang F.L., Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996, 65:241-269.
26. Olson M.F., Ashworth A., Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 1995, 269:1270-1272.
27. Macaluso M., Russo G., Cinti C., Bazan V., Gebbia N., Russo A. Ras family genes: an interesting link between cell cycle and cancer. J Cell Physiol 2002, 192:125-130.
28. Widegren U., Wretman C., Lionikas A., Hedin G., Henriksson J. Influence of exercise intensity on ERK/MAP kinase signalling in human skeletal muscle. Pflugers Arch 2000, 441:317-322.
29. Krook A., Widegren U., Jiang X.J., et al. Effects of exercise on mitogen- and stress-activated kinase signal transduction in human skeletal muscle. Am J Physiol Regul Integr Comp Physiol 2000, 279:R1716-R1721.
30. Meador B.M., Huey K.A. Statin-associated changes in skeletal muscle function and stress response after novel or accustomed exercise. Muscle Nerve 2011, 44:882-889.
31. Thompson P.D., Zmuda J.M., Domalik L.J., Zimet R.J., Staggers J., Guyton J.R. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997, 46:1206-1210.
32. Folkers K., Langsjoen P., Willis R., et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990, 87:8931-8934.
33. De Pinieux G., Chariot P., Ammi-Said M., et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996, 42:333-337.
34. Jamal S.M., Eisenberg M.J., Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 2004, 147:956-965.
35. Owczarek J., Jasinska M., Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep 2005, 57:23-34.
36. Marcoff L., Thompson P.D. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007, 49:2231-2237.
37. Phillips P.S., Haas R.H., Bannykh S., et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002, 137:581-585.
38. Lamperti C., Naini A.B., Lucchini V., et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 2005, 62:1709-1712.
39. Gambelli S., Dotti M.T., Malandrini A., et al. Mitochondrial alterations in muscle biopsies of patients on statin therapy. J Submicrosc Cytol Pathol 2004, 36:85-89.
40. Thibault A., Samid D., Tompkins A.C., et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996, 2:483-491.
41. Caso G., Kelly P., McNurlan M.A., Lawson W.E. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007, 99:1409-1412.
42. Young J.M., Florkowski C.M., Molyneux S.L., McEwan R.G., Framptom C.M., George P.M. Coenzyme Q10 does not improve simvastatin tolerability in dyslipidemic patients with prior statin-induced myalgia. Am J Cardiol 2007, 100:1400-1403.
43. Chariot P., Abadia R., Agnus D., Danan C., Charpentier C., Gherardi R.K. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med 1993, 94:109-110.
44. Thomas J.E., Lee N., Thompson P.D. Statins provoking MELAS syndrome. A case report. Eur Neurol 2007, 57:232-235.
45. Golomb B.A., Evans M.A. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008, 8:373-418.
46. Negre-Aminou P., van Vliet A.K., van Erck M., van Thiel G.C., van Leeuwen R.E., Cohen L.H. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997, 1345:259-268.
47. Buemi M., Allegra A., Senatore M., et al. Pro-apoptotic effect of fluvastatin on human smooth muscle cells. Eur J Pharmacol 1999, 370:201-203.
48. Guijarro C., Blanco-Colio L.M., Ortego M., et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998, 83:490-500.
49. Hanai J., Cao P., Tanksale P., et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 2007, 117:3940-3951.
50. Mohaupt M.G., Karas R.H., Babiychuk E.B., et al. Association between statin-associated myopathy and skeletal muscle damage. CMAJ 2009, 181:E11-E18.
51. Kobashigawa J.A. Statins and cardiac allograft vasculopathy after heart transplantation. Semin Vasc Med 2004, 4:401-406.
52. Kwak B., Mulhaupt F., Veillard N., Pelli G., Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swis Med Wkly 2001, 131:41-46.
53. Fehr T., Kahlert C., Fierz W., et al. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 2004, 175:83-90.
54. Nath N., Giri S., Prasad R., Singh A.K., Singh I. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol 2004, 172:1273-1286.
55. Youssef S., Stuve O., Patarroyo J.C., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420:78-84.
56. Mammen A.L., Chung T., Christopher-Stine L., et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011, 63:713-721.
57. Liang C., Needham M. Necrotizing autoimmune myopathy. Curr Opin Rheumatol 2011, 23:612-619.
58. Grable-Esposito P., Katzberg H.D., Greenberg S.A., Srinivasan J., Katz J., Amato A.A. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010, 41:185-190.
59. Needham M., Fabian V., Knezevic W., Panegyres P., Zilko P., Mastaglia F.L. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007, 17:194-200.
60. Mohassel P., Mammen A.L. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies: a review. Muscle Nerve 2013, 48:477-483.
61. Mastaglia F.L., Needham M. Update on toxic myopathies. Curr Neurol Neurosci Rep 2012, 12:54-61.
62. Fauchais A.L., Iba Ba J., Maurage P., et al. Polymyositis induced or associated with lipid-lowering drugs: five cases. Rev Med Intern 2004, 25:294-298.
63. Takagi A., Shiio Y. Pravastatin-associated polymyositis, a case report. Rinsho Shinkeigaku 2004, 44:25-27.
64. Riesco-Eizaguirre G., Arpa-Gutierrez F.J., Gutierrez M., Toribio E. Severe polymyositis with simvastatin use. Rev Neurol 2003, 37:934-936.
65. Giordano N., Senesi M., Mattii G., Battisti E., Villanova M., Gennari C. Polymyositis associated with simvastatin. Lancet 1997, 349:1600-1601.
66. Khattak F., Morris I., Branford W. Simvastatin-associated dermatomyositis. Br J Rheumatol 1993, 32:647-648.
67. Vasconcelos O.M., Campbell W.W. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 2004, 30:803-807.
68. CJaPR Noel B. Atorvastatin induced dermatomyositis. Am J Med 2001, 110:670-671.
69. Hill C., Zeitz C., Kirkham B. Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust N Z J Med 1995, 25:745-746.
70. Rodriguez-Garcia J., Serrano C. Lovastatin-associated dermatomyositis. Postgrad Med J 1996, 72:694.
71. Zuech P., Pauwels C., Duthoit C., et al. Pravastatin-induced dermatomyositis. Rev Med Intern 2005, 26:897-902.
72. Cartwright M.S., Jeffery D.R., Nuss G.R., Donofrio P.D. Statin-associated exacerbation of myasthenia gravis. Neurology 2004, 63:2188.
73. Purvin V., Kawasaki A., Smith K.H., Kesler A. Statin-associated myasthenia gravis: report of 4 cases and review of the literature. Medicine (Baltimore) 2006, 85:82-85.
74. Hawwa A.F., Millership J.S., Collier P.S., et al. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol 2008, 66:517-528.
75. Whirl-Carrillo M., McDonagh E.M., Hebert J.M., et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012, 92:414-417.
76. Wilke R.A., Lin D.W., Roden D.M., et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007, 6:904-916.
77. FDA, News, Release. FDA approves updated warfarin (Coumadin) prescribing information. 2007 [cited 2012 10.12.12]; Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108967.htm.
78. Nestel P., Simons L., Barter P., et al. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. Atherosclerosis 1997, 129:231-239.
79. Ordovas J.M., Lopez-Miranda J., Perez-Jimenez F., et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995, 113:157-166.
80. Pedro-Botet J., Schaefer E.J., Bakker-Arkema R.G., et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001, 158:183-193.
81. Ballantyne C.M., Herd J.A., Stein E.A., et al. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol 2000, 36:1572-1578.
82. Chasman D.I., Posada D., Subrahmanyan L., Cook N.R., Stanton V.P., Ridker P.M. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004, 291:2821-2827.
83. Salazar L.A., Hirata M.H., Quintao E.C., Hirata R.D. Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia. J Clin Lab Anal 2000, 14:125-131.
84. Winkelmann B.R., Hoffmann M.M., Nauck M., et al. Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy. Pharmacogenomics J 2003, 3:284-296.
85. Marian A.J., Safavi F., Ferlic L., Dunn J.K., Gotto A.M., Ballantyne C.M. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol 2000, 35:89-95.
86. Maitland-van der Zee A.H., Boerwinkle E. Pharmacogenetics of response to statins: where do we stand?. Curr Atheroscler Rep 2005, 7:204-208.
87. Hirschhorn J.N., Lohmueller K., Byrne E., Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002, 4:45-61.
88. Giorgi M.A., Caroli C., Arazi H.C., Di Girolamo G. Pharmacogenomics and adverse drug reactions: the case of statins. Expert Opin Pharmacother 2011, 12:1499-1509.
89. *11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken) 2012, 64:1233-1237.
90. Vladutiu G.D. Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008, 20:648-655.
91. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007, 8:787-802.
92. Romaine S.P., Bailey K.M., Hall A.S., Balmforth A.J. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 2010, 10:1-11.
93. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 2010, 87:130-133.
94. *5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009, 54:1609-1616.
95. Pasanen M.K., Neuvonen M., Neuvonen P.J., Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006, 16:873-879.
96. Niemi M., Pasanen M.K., Neuvonen P.J. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006, 80:356-366.
97. SEARCH CG, Link E., Parish S., et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008, 359:789-799.
98. Donnelly L.A., Doney A.S., Tavendale R., et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther 2011, 89:210-216.
99. Morimoto K., Oishi T., Ueda S., Ueda M., Hosokawa M., Chiba K. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab Pharmacokinet 2004, 19:453-455.
100. Wilke R.A., Ramsey L.B., Johnson S.G., et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 2012, 92:112-117.
101. FDA. FDA: Limit Use of 80 mg Simvastatin. Consumer updates 2011 04-17-2013 [cited 2013 03-30-2013] http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm%5D.
102. Fiegenbaum M., da Silveira F.R., Van der Sand C.R., et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005, 78:551-558.
103. Kajinami K., Brousseau M.E., Ordovas J.M., Schaefer E.J. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 2004, 93:1046-1050.
104. Transon C., Leemann T., Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996, 50:209-215.
105. Abbott A. With your genes? Take one of these, three times a day. Nature 2003, 425:760-762.
106. Vermes A., Vermes I. Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs 2004, 4:247-255.
107. Wilke R.A., Moore J.H., Burmester J.K. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics 2005, 15:415-421.
108. *4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet Genomics 2007, 17:695-707.
109. Sachse C., Brockmoller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997, 60:284-295.
110. Mulder A.B., van Lijf H.J., Bon M.A., et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther 2001, 70:546-551.
111. Zuccaro P., Mombelli G., Calabresi L., Baldassarre D., Palmi I., Sirtori C.R. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol Res 2007, 55:310-317.
112. Kirchheiner J., Kudlicz D., Meisel C., et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 2003, 74:186-194.
113. Sabia H., Prasad P., Smith H.T., Stoltz R.R., Rothenberg P. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia. J Cardiovasc Pharmacol 2001, 37:502-511.
114. Baker S.K., Samjoo I.A. A neuromuscular approach to statin-related myotoxicity. Can J Neurol Sci 2008, 35:8-21.
115. Lorenzoni P.J., Silvado C.E., Scola R.H., Luvizotto M., Werneck L.C. McArdle disease with rhabdomyolysis induced by rosuvastatin: case report. Arq Neuropsiquiatr 2007, 65:834-837.
116. Barth J.H., Brownjohn A.M., Jamieson D.R. The case of stainless statins. Ann Clin Biochem 2003, 40:576-577.
117. Livingstone C., Al Riyami S., Wilkins P., Ferns G.A. McArdle's disease diagnosed following statin-induced myositis. Ann Clin Biochem 2004, 41:338-340.
118. Voermans N.C., Lammens M., Wevers R.A., Hermus A.R., van Engelen B.G. Statin-disclosed acid maltase deficiency. J Intern Med 2005, 258:196-197.
119. Melli G., Chaudhry V., Cornblath D.R. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005, 84:377-385.
120. Vladutiu G.D., Simmons Z., Isackson P.J., et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006, 34:153-162.
121. Guis S., Figarella-Branger D., Mattei J.P., et al. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis Rheum 2006, 55:551-557.
122. Vladutiu G. Statin-induced adverse effects and malignant hyperthermia susceptibility: comment on the article by Guis et al. Arthritis Rheum 2007, 57:186-187. [author reply 187-8].
123. Vladutiu G.D., Isackson P.J., Kaufman K., et al. Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies. Mol Genet Metab 2011, 104:167-173.
124. Marciante K.D., Durda J.P., Heckbert S.R., et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics 2011, 21:280-288.
125. Tay S.K., Dimauro S., Pang A.Y., Lai P.S., Yap H.K. Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation. Pediatr Neurol 2008, 39:426-428.
126. Oh J., Ban M.R., Miskie B.A., Pollex R.L., Hegele R.A. Genetic determinants of statin intolerance. Lipids Health Dis 2007, 6:7.
127. Quinzii C., Naini A., Salviati L., et al. A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet 2006, 78:345-349.
128. Zeharia A., Shaag A., Houtkooper R.H., et al. Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood. Am J Hum Genet 2008, 83:489-494.
129. Sailler L., Pereira C., Bagheri A., et al. Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study. Ann Rheum Dis 2008, 67:614-619.
130. Draeger A., Sanchez-Freire V., Monastyrskaya K., et al. Statin therapy and the expression of genes that regulate calcium homeostasis and membrane repair in skeletal muscle. Am J Pathol 2010, 177:291-299.
131. Ruano G., Thompson P.D., Windemuth A., et al. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve 2007, 36:329-335.
132. Ruano G., Thompson P.D., Windemuth A., et al. Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics 2005, 6:865-872.
133. Scarpini F., Cappellone R., Auteri A., Puccetti L. Role of genetic factors in statins side-effects. Cardiovasc Hematol Disord Drug Targets 2012, 12:35-43.
134. Limdi N.A., Veenstra D.L. Expectations, validity, and reality in pharmacogenetics. J Clin Epidemiol 2010, 63:960-969.
135. Joy T.R., Hegele R.A. Narrative review: statin-related myopathy. Ann Intern Med 2009, 150:858-868.
136. Bar S.L., Holmes D.T., Frohlich J. Asymptomatic hypothyroidism and statin-induced myopathy. Can Fam Physician 2007, 53:428-431.
137. Ahmed W., Khan N., Glueck C.J., et al. Low serum 25 (OH) vitamin D levels (<32ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009, 153:11-16.
138. Schmitz G., Drobnik W. Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy. Clin Chem Lab Med 2003, 41:581-589.
139. Zhou S., Yung Chan S., Cher Goh B., et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005, 44:279-304.
140. Zhou S., Chan E., Li X., Huang M. Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Ther Clin Risk Manag 2005, 1:3-13.
141. Ray G.M. Antiretroviral and statin drug-drug interactions. Cardiol Rev 2009, 17:44-47.
142. Backman J.T., Kyrklund C., Kivisto K.T., Wang J.S., Neuvonen P.J. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000, 68:122-129.
143. Kyrklund C., Backman J.T., Neuvonen M., Neuvonen P.J. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003, 73:538-544.
144. Schneck D.W., Birmingham B.K., Zalikowski J.A., et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004, 75:455-463.
145. Kyrklund C., Backman J.T., Kivisto K.T., Neuvonen M., Laitila J., Neuvonen P.J. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001, 69:340-345.
146. Becquemont L., Neuvonen M., Verstuyft C., et al. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clin Pharmacol Ther 2007, 81:679-684.
147. Kyriakides T., Angelini C., Schaefer J., et al. EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol 2010, 17:767-773.